Quick Summary:
Realize the potential for growth and gain essential competitive edge in the burgeoning open-angle glaucoma therapeutics market. Our comprehensive market research report supplies holistic analysis coupled with up-to-the-minute trends, drivers, challenges, and robust vendor insights covering around 25 leading market players, providing a thorough overview of the current market landscape. Driven by promising pipeline and recent approvals, rising demand for combination drugs and an expanding geriatric population, acquisition of this report will put you at the forefront of this expanding market.
Segmented by channel (hospital, retail, and online pharmacies), product (PGAs and non-PGAs), and geographical landscape, this research sense-checks market sizing and forecasts, and provides invaluable industry analysis. The report identifies significant growth drivers such as the advent of biologics, an increase in strategic alliances, and rising awareness about glaucoma. Gain the advantage in leveraging growth opportunities by understanding the forthcoming market trends and challenges. A product of extensive research, this report combines primary and secondary data, providing a comprehensive, reliable and analytically rigorous picture of the market.
Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by promising pipeline and recent approvals, increasing demand for combination drugs, and rising geriatric population.
The open-angle glaucoma therapeutics market is segmented as below:
By Channel
- Hospital pharmacy
- Retail pharmacy
- Online pharmacy
By Product
- PGAs
- Non-PGAs
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the open-angle glaucoma therapeutics market covers the following areas:
- Open-angle glaucoma therapeutics market sizing
- Open-angle glaucoma therapeutics market forecast
- Open-angle glaucoma therapeutics market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
Executive Summary
The publisher recognizes the following companies as the key players in the global open-angle glaucoma therapeutics market: AbbVie Inc., Alcon Inc., Bausch Health Companies Inc., D.Western Therapeutics Institute Inc, Hikma Pharmaceuticals Plc, Inotek Pharmaceuticals, Merck and Co. Inc., Nicox S.A., Novartis AG, Ocuphire Pharma Inc, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Santen Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is development of biologics.'
According to the report, one of the major drivers for this market is the promising pipeline and recent approvals.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned
A selection of companies mentioned in this report includes:
- AbbVie Inc.
- Alcon Inc.
- Bausch Health Companies Inc.
- D.Western Therapeutics Institute Inc
- Hikma Pharmaceuticals Plc
- Inotek Pharmaceuticals
- Merck and Co. Inc.
- Nicox S.A.
- Novartis AG
- Ocuphire Pharma Inc
- Otsuka Pharmaceutical Co. Ltd.
- Pfizer Inc.
- Santen Pharmaceutical Co. Ltd.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
